Jones Financial Companies’s Enveric Biosciences ENVB Stock Holding History

Jones Financial Companies’s Portfolio ENVB Stock Details ENVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.88K	Buy	+1,000	New	+$2.73K	﹤0.01%	4165
2025 Q3	–	Hold	0	–	-$1	–	4272
2025 Q2	–	Hold	0	–	–	–	4027

Other funds holding ENVB

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Jones Financial Companies's ENVB Position: Q1 2026 in Review

Jones Financial Companies opened a new position in Enveric Biosciences (ENVB) in Q1 2026: 1,000 shares worth $1.88K. The stake represents ﹤0.01% of the portfolio and ranks #4165 among its holdings.

11 funds tracked by Wall St. Rank hold ENVB as of Q1 2026.

Jones Financial Companies held 1,000 shares of Enveric Biosciences worth $1.88K as of Q1 2026.
Enveric Biosciences was a new Jones Financial Companies position in Q1 2026.
Enveric Biosciences made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #4165 holding.
11 funds tracked by Wall St. Rank held Enveric Biosciences as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.